[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-type-adenocarcinoma-gas-with-stk11-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-type-adenocarcinoma-gas-with-stk11-mutation":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100525686",false,"NCT06124963","A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations","A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations","Inclusion Criteria:\n\n* ≥18 years of age\n* Histological or cytological confirmed advanced Gastric-type Endocervical Adenocarcinoma.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Life expectancy of more than 3 months\n* At least one measurable lesion according to RECIST 1.1\n* Adequate organic function\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 30 days prior to the initiation of investigational treatment\n* Major surgery within 30 days prior to the initiation of study treatment\n* Received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment\n* Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia)\n* Patients who are suffering active interstitial lung disease\n* Evidence of ongoing or active serious infection\n* History of human immunodeficiency virus (HIV) infection or active hepatitis B or C infection\n* Inability to take medication orally\n* Abuse of alcohol or drugs\n* People with cognitive and psychological abnormality or with low compliance\n* Pregnant or lactating women","FEMALE","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are:\n\n* Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment.\n* Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.",[25],"Gastric Type Adenocarcinoma (GAS) With STK11 Mutation","RECRUITING","2024-12-09",{"date":29,"type":30},"2024-12-10","ACTUAL",{"date":32,"type":30},"2023-08-25",{"date":34,"type":19},"2026-12-09",{"name":36,"class":37},"Shanghai Jiatan Pharmatech Co., Ltd","INDUSTRY",""]